Avadel Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2021 Financial Results
- Commercial and launch preparations on track to support potential U.S. FDA approval of FT218 for the treatment of excessive daytime sleepiness and cataplexy in adults suffering from narcolepsy
- Presentation of post hoc analyses from pivotal REST-ON clinical…
